Frequency and Clinical Significance Anti-PS/PT Antibodies in Patients with Antiphospholipid Syndrome—Single Centre Observational Study in the United Kingdom

Hithin Noble; Christina Crossette-Thambiah; Zain Odho; Nilanthi Karawitage; Karen Logan; Charis Pericleous; Mike Laffan; Deepa R.J. Arachchillage

doi:10.1055/s-0042-1757633

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2023; 49(05): 553-557
DOI: 10.1055/s-0042-1757633

Review Article

Frequency and Clinical Significance Anti-PS/PT Antibodies in Patients with Antiphospholipid Syndrome—Single Centre Observational Study in the United Kingdom

Hithin Noble‡^*

¹Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom

,

Christina Crossette-Thambiah‡^*

¹Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom

²Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom

,

Zain Odho

³Department of Laboratory medicine, Royal Brompton Hospital, London, United Kingdom

,

Nilanthi Karawitage

¹Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom

,

Karen Logan

¹Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom

,

Charis Pericleous

⁴National Heart and Lung Institute, Imperial College London, London, United Kingdom

,

Mike Laffan

¹Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom

²Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom

,

Deepa R.J. Arachchillage

¹Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom

²Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom

References
1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
2 Pontara E, Cattini MG, Cheng C, Bison E, Denas G, Pengo V. Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of aβ2GPI and aPS/PT antibodies. J Thromb Haemost 2021; 19 (03) 805-813
3 Cattini MG, Bison E, Pontara E, Cheng C, Denas G, Pengo V. Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity. J Thromb Haemost 2020; 18 (05) 1124-1132
4 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014; 111 (02) 354-364
5 Jaskowski TD, Wilson AR, Hill HR, Branch WD, Tebo AE. Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome?. Clin Chim Acta 2009; 410 (1-2): 19-24
6 Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86 (01) 83-91
7 Žigon P, Perdan Pirkmajer K, Tomšič M. et al. Anti-phosphatidylserine/prothrombin antibodies are associated with adverse pregnancy outcomes. J Immunol Res 2015; 2015: 975704
8 Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost 2016; 14 (04) 675-684
9 Shi H, Zheng H, Yin YF. et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med 2018; 56 (04) 614-624
10 Pregnolato F, Chighizola CB, Encabo S. et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. Immunol Res 2013; 56 (2-3): 432-438
11 Devreese K, Hoylaerts MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem 2010; 56 (06) 930-940
12 de Laat B, Pengo V, Pabinger I. et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7 (11) 1767-1773
13 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
14 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66 (06) 629-632
15 Pham M, Orsolini G, Crowson C, Snyder M, Pruthi R, Moder K. Anti-phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all-comer population. J Thromb Haemost 2022; 20 (09) 2070-2074
16 Dienava-Verdoold I, Boon-Spijker MG, de Groot PG. et al. Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity. J Thromb Haemost 2011; 9 (04) 738-747
17 Lai CJ, Rauch J, Cho CS, Zhao Y, Chukwuocha RU, Chen PP. Immunological and molecular analysis of three monoclonal lupus anticoagulant antibodies from a patient with systemic lupus erythematosus. J Autoimmun 1998; 11 (01) 39-51
18 Sayar Z, Moll R, Isenberg D, Cohen H. Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management. Thromb Res 2021; 198: 213-221
19 Arachchillage DR, Mackie IJ, Efthymiou M, Isenberg DA, Machin SJ, Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 2015; 13 (07) 1264-1273
20 Cox-Morton S, MacDonald S, Thomas W. A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove. Br J Haematol 2019; 187 (03) 377-385
21 Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples. Thromb Res 2018; 163: 117-122
22 Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol 2017; 178 (02) 181-195
23 Vlagea A, Gil A, Cuesta MV. et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost 2013; 19 (03) 289-296
24 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (02) 237-242
25 Oku K, Amengual O, Zigon P, Horita T, Yasuda S, Atsumi T. Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology (Oxford) 2013; 52 (10) 1775-1784

Zusatzmaterial

Supplementary Material